Mylicon

Simeticone

Simeticone

Anti-foaming agent used to reduce bloating, discomfort or pain caused by excessive gas

Simeticone (INN), also known as simethicone (USAN), is an anti-foaming agent used to reduce bloating, discomfort or pain caused by excessive gas.

Quick Facts Clinical data, Trade names ...

Medical uses

Simethicone tablets

Simeticone is used to relieve the symptoms of excessive gas in the gastrointestinal tract, namely bloating, burping, and flatulence.[2][3] While there is a lack of conclusive evidence that simeticone is effective for this use,⁣[4][5][failed verification] studies have shown that it can relieve symptoms of functional dyspepsia[6] and functional bloating.[7]

It has not been fully established that simeticone is useful to treat colic in babies,[8] and it is not recommended for this purpose.[5] A study in the United Kingdom reported that according to parental perception simeticone helped infant colic in some cases.[9]

Simeticone can also be used for suspected postoperative abdominal discomfort in infants.[10]

Side effects

Simeticone does not have any serious side effects.[11] Two uncommon side effects (occurring in 1 in 100 to 1 in 1,000 patients) are constipation and nausea.[12]

Pharmacology

Simeticone is a non-systemic surfactant which decreases the surface tension of gas bubbles in the GI tract.[11] This allows gas bubbles to leave the GI tract as flatulence or belching.[11] Simeticone does not reduce or prevent the formation of gas.[13] Its effectiveness has been shown in several in vitro studies.[14][15]

Chemistry

Simeticone is a mixture of dimethicone and silicon dioxide.[16]

Names

The INN name is "simeticone", which was added to the INN recommended list in 1999.[17]

Simeticone is marketed under many brand names and in many combination drugs; it is also marketed as a veterinary drug.[18]

More information Brands ...

References

  1. [1]
    "Simethicone names". Drugs.com. Retrieved 27 August 2017.
  2. [2]
    "Simethicone tablet". NIH DailyMed. April 2016. Retrieved 27 August 2017.
  3. [3]
    "Simeticone". NHS. 10 October 2019. Retrieved 30 January 2020.
  4. [4]
    Modi R, Clearfield HR, Levitt M (July 2013). "Belching, Bloating and Flatulence". American College of Gastroenterology.
  5. [5]
    "Simethicone". drugs.com. Efficacy not established for the symptomatic relief of immediate postprandial upper abdominal distress
  6. [6]
    Holtmann G, Gschossmann J, Mayr P, Talley NJ (September 2002). "A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia". Alimentary Pharmacology & Therapeutics. 16 (9). Wiley: 1641–8. doi:10.1046/j.1365-2036.2002.01322.x. PMID 12197843. S2CID 23286985.
  7. [7]
    Burta O, Iacobescu C, Mateescu RB, Nicolaie T, Tiuca N, Pop CS (25 September 2018). "Efficacy and safety of APT036 versus simethicone in the treatment of functional bloating: a multicentre, randomised, double-blind, parallel group, clinical study". Translational Gastroenterology and Hepatology. 3 (72). AME Publications: 72. doi:10.21037/tgh.2018.09.11. PMC 6256934. PMID 30511026.
  8. [8]
    Biagioli E, Tarasco V, Lingua C, Moja L, Savino F (September 2016). "Pain-relieving agents for infantile colic". The Cochrane Database of Systematic Reviews. 2016 (9): CD009999. doi:10.1002/14651858.CD009999.pub2. PMC 6457752. PMID 27631535.
  9. [9]
    Goldman M, Beaumont T (March 2017). "A real world evaluation of a treatment for infant colic based on the experience and perceptions of 4004 parents". British Journal of Nursing. 26 (5 Suppl 1): S3–S10. doi:10.12968/bjon.2017.26.Sup5.S3. PMID 28350192. S2CID 32885530.
  10. [10]
    Voepel-Lewis TD, Malviya S, Burke C, D'Agostino R, Hadden SM, Siewert M, Tait AR (March 1998). "Evaluation of simethicone for the treatment of postoperative abdominal discomfort in infants". Journal of Clinical Anesthesia. 10 (2): 91–94. doi:10.1016/S0952-8180(97)00249-3. PMID 9524891.
  11. [11]
    Ingold CJ, Akhondi H (January 2021). "Simethicone". StatPearls [Internet]. PMID 32310457.
  12. [12]
    "Simethicone Side Effects in Detail". Drugs.com. Retrieved 27 August 2017.
  13. [13]
    "Treatment of Gas". International Foundation for Functional Gastrointestinal Disorders. 4 September 2015.
  14. [14]
    Brecević L, Bosan-Kilibarda I, Strajnar F (May 1994). "Mechanism of antifoaming action of simethicone". Journal of Applied Toxicology. 14 (3). Wiley: 207–11. doi:10.1002/jat.2550140311. PMID 8083482. S2CID 7453218. Retrieved 30 January 2020.
  15. [15]
    Dittrich M, Miederer SE, Havertz B, Krastev R (12 May 2010). "Schaumzerstörung und Schaumverhinderung: Der Wirkmechanismus von Simeticon in vitro" [Defoaming and antifoaming action of simethicone in vitro] (PDF). Journal für Gastroenterologische und Hepatologische Erkrankungen. (in German). 8 (3). Krause & Pachernegg: 19–25.
  16. [16]
    O'Neil MJ, ed. (2006). "Dimethicone". The Merck Index (14th ed.). Whitehouse Station, NJ: Merck. p. 545.
  17. [17]
    "Recommended INN List 42" (PDF). WHO Drug Information. 13 (3): 202. 1999.
  18. [18]
    "Simeticone international brands". Drugs.com. Retrieved 27 August 2017.
Share this article:

This article uses material from the Wikipedia article Mylicon, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.